RESEARCHER PROFILE

Roberto Bianco

← Back to University of Naples Federico II

R

University of Naples Federico II

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchBreast Cancer Treatment StudiesAdvanced Breast Cancer TherapiesColorectal Cancer Treatments and Studies

Roberto Bianco works in Lung Cancer Treatments and Mutations, HER2/EGFR in Cancer Research, Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, Colorectal Cancer Treatments and Studies. Recorded institutional associations include Federico II University Hospital, University of Naples Federico II.

506Publications
12,356Citations
58H-index

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

    2000 · 937 citations
  2. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

    2001 · 643 citations
  3. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.

    2001 · 548 citations
  4. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

    2003 · 448 citations
  5. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.

    2000 · 379 citations
  6. Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project

    1999 · 362 citations
  7. Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy

    2004 · 349 citations
  8. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.

    1999 · 332 citations
  9. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).

    2002 · 246 citations
  10. Role of early ultrasound in detecting inflammatory intestinal disorders and identifying their anatomical location within the bowel

    2003 · 220 citations
  11. Role of FGFR3 in bladder cancer: Treatment landscape and future challenges

    2023 · 211 citations
  12. Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications

    2019 · 200 citations
  13. Chagas disease in Europe: A review for the internist in the globalized world

    2017 · 199 citations
  14. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients

    2005 · 179 citations
  15. Mechanisms of lapatinib resistance in HER2-driven breast cancer

    2015 · 164 citations
  16. Key cancer cell signal transduction pathways as therapeutic targets

    2006 · 153 citations
  17. Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells

    2013 · 152 citations
  18. Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells

    2008 · 149 citations
  19. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.

    2003 · 148 citations
  20. Rational bases for the development of EGFR inhibitors for cancer treatment

    2007 · 144 citations
  21. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs

    2008 · 135 citations
  22. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer

    2017 · 132 citations
  23. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.

    2000 · 126 citations
  24. Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy

    2006 · 125 citations
  25. The Novel Butyrate Derivative Phenylalanine-Butyramide Protects from Doxorubicin-Induced Cardiotoxicity

    2019 · 123 citations

← Return to the university profile